Nekacin (Amikacin Sulfate)

Amikacin, the active ingredient in Nekacin, is an aminoglycoside antibiotic presented as a sterile injectable solution for intramuscular and intravenous use. It is employed to treat serious infections caused by susceptible Gram‑negative bacteria, particularly in hospitalized patients and those requiring parenteral therapy.

GNH USA supplies Nekacin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres and pharmacies worldwide. The company adheres to EU quality standards and provides reliable logistics for bulk and unit‑dose requirements. Customer support is available for regulatory and technical queries.

Amikacin is an aminoglycoside antibiotic used to treat infections caused by susceptible Gram‑negative bacteria.

- Septicemia: eradicates bloodstream infections caused by susceptible Gram‑negative organisms. - Hospital‑acquired pneumonia: improves outcomes in ventilator‑associated or nosocomial pneumonia due to resistant Gram‑negative pathogens. - Complicated urinary tract infection: clears infections where other agents are ineffective. - Intra‑abdominal infection: treats peritonitis and intra‑abdominal sepsis caused by susceptible bacteria. - Skin and soft‑tissue infection: resolves severe cellulitis or wound infections with Gram‑negative involvement.

Amikacin may be associated with adverse reactions that vary in frequency and severity.

Common Side Effects: - Nephrotoxicity: rise in serum creatinine or reduced glomerular filtration. - Ototoxicity (auditory): transient hearing loss or tinnitus. - Vestibular dysfunction: dizziness or balance disturbances. - Rash or mild fever: skin reactions or low‑grade pyrexia.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction with respiratory compromise. - Irreversible hearing loss: permanent auditory damage at high doses. - Severe nephrotoxicity: acute kidney injury requiring intervention. - Stevens‑Johnson syndrome: extensive skin detachment and mucosal involvement.

When using Amikacin, clinicians should observe several safety measures.

- Renal function monitoring: assess serum creatinine before and during therapy. - Auditory function monitoring: perform baseline and periodic audiometry. - Dosage adjustment in renal impairment: reduce dose according to clearance. - Avoid concurrent nephrotoxic drugs: limit use with vancomycin, amphotericin B, loop diuretics, or NSAIDs. - Pregnancy and lactation: use only if benefits outweigh risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Amikacin can interact with other medicines, requiring attention to avoid increased toxicity.

Major Interactions (Avoid): - Concurrent nephrotoxic agents (e.g., vancomycin, amphotericin B, loop diuretics): heightened risk of kidney injury. - Ototoxic drugs (e.g., furosemide, cisplatin): additive hearing loss. - Neuromuscular blocking agents (e.g., succinylcholine, pancuronium): potentiated blockade. - Probenecid: reduced renal clearance, increasing serum levels.

Moderate Interactions (Monitor Closely): - Other aminoglycosides: cumulative toxicity; monitor serum concentrations. - Diuretics: may exacerbate renal effects; observe renal function. - Neuromuscular blockers: enhanced muscle weakness; assess neuromuscular status.